Rapid Tyrosine Phosphorylation of Neuronal Proteins Including Tau and Focal Adhesion Kinase in Response to Amyloid-β Peptide Exposure: Involvement of Src Family Protein Kinases

Ritchie Williamson,1 Timothy Scales,1 Bruce R. Clark,1 Graham Gibb,1 C. Hugh Reynolds,1 Stuart Kellie,3 Ian N. Bird,3 Ian M. Varneddell,4 Paul W. Sheppard,4 Ian Everali,4 and Brian H. Anderton1

Department of 1Neuroscience, 2Section of Experimental Neuropathology and Psychiatry, Institute of Psychiatry, King’s College London, London SE5 8AF, United Kingdom, 3Yamanouchi Research Institute, Littlemore Park, Oxford OX4 4SX, United Kingdom, and 4Affiniti Research Products Limited, Mamhead Castle, Mamhead, Exeter EX6 8HD, United Kingdom

The increased production of amyloid β-peptide (Aβ) in Alzheimer’s disease is acknowledged to be a key pathogenic event. In this study, we examined the response of primary human and rat brain cortical cultures to Aβ administration and found a marked increase in the tyrosine phosphorylation content of numerous neuronal proteins, including tau and putative microtubule-associated protein 2c (MAP2c). We also found that paired helical filaments of aggregated and hyperphosphorylated tau are tyrosine phosphorylated, indicating that changes in the phosphotyrosine content of cytoplasmic proteins in response to Aβ are potentially an important process. Increased tyrosine phosphorylation of cytoskeletal and other neuronal proteins was specific to fibrillar Aβ25-35 and Aβ1-42. The tyrosine phosphorylation was blocked by addition of the Src family tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7((1-butyl)pyrazolo[3,4-$d$]pyrimide (PP2) and the phosphatidylinositol 3-kinase inhibitor LY 294002. Tyrosine phosphorylation of tau and MAP2c was concomitant with an increase in the tyrosine phosphorylation and subsequent putative activation of the non-receptor kinase, focal adhesion kinase (FAK). Immunoprecipitation of Fyn, a member of the Src family, from Aβ25-35-treated neurons showed an increased association of Fyn with FAK. Aβ treatment of cells also stimulated the sustained activation of extracellular regulated kinase-2, which was blocked by addition of PP2 and LY 294002, suggesting that FAK/Fyn/PI3-kinase association is upstream of mitogen-activated protein (MAP) kinase signaling in Aβ-treated neurons. This cascade of signaling events contains the earliest biochemical changes in neurons to be described in response to Aβ exposure and may be critical for subsequent neurodegenerative changes.

Key words: Alzheimer’s disease; amyloid β-peptide; cortical neurons; tyrosine phosphorylation; FAK; Fyn; ERK2; tau; MAP2c

Neurofibrillary tangles and senile neuritic plaques with an extracellular core of amyloid are the pathological lesions in the brain in Alzheimer’s disease (Smith and Anderton, 1994). Although deposition of amyloid β-peptide (Aβ) is an early event as Alzheimer’s disease (AD) develops, it is not clear how tangles subsequently form. Neurofibrillary tangles are composed of paired helical filaments of aggregated and hyperphosphorylated tau (PHF-tau) (Lovestone et al., 1994; Hanger et al., 1998). Several laboratories have reported that Aβ treatment of neurons in primary culture results in an elevation in tau phosphorylation, indicative of a link between Aβ deposition and tau pathology (Buciglio et al., 1995).

In these previous studies, changes in the phosphorylation state of tau were usually observed after prolonged exposure to Aβ. The protein kinases implicated in phosphorylating tau in response to Aβ treatment include the extracellular regulated kinase-1 (ERK1) and ERK2 (McDonald et al., 1998; Pyo et al., 1998; Rapoport and Ferreira, 2000), cyclin-dependent kinase-5 (Imahori and Uchida, 1997; A. Alvarez et al., 1999; Lee et al., 2000), and glycogen synthase kinase-3α and -3β (GSK-3α and -3β) (Takashima et al., 1998). Other studies of the effects of Aβ on cells have shown that certain parameters are affected within shorter periods. These include activation of the protein tyrosine kinase (PTK) Lyn in microglial cells (McDonald et al., 1998), increased tyrosine phosphorylation and Ca$^{2+}$ influx (Luo et al., 1995), activation of phosphatidylinositol 3-kinase (PI3-kinase) (Luo et al., 1996), cAMP response element-binding protein phosphorylation (Sato et al., 1997), increased oxidative stress (Ekinci et al., 2000), and finally apoptosis (Harada and Sugimoto, 1999).

The tyrosine kinase Fyn is upregulated in a subset of neurons in AD brain that also contain hyperphosphorylated tau (Shirazi and Wood, 1993). Fyn knock-out mice display specific neurological deficits (Grant et al., 1992), and brain slices from Fyn knock-out mice are completely protected from Aβ-derived diffusible ligand (ADDL) toxicity (Lambert et al., 1998). Fyn is associated with tyrosine phosphorylated tau in neuronal cells, and Fyn may activate the serine/threonine kinase, GSK-3B, a tau kinase that can hyperphosphorylate tau (Lee et al., 1998; Lesort et al., 1999).

Here we report that treatment of primary human and rat cortical neuronal cultures with fibrillar Aβ resulted in a rapid increase in the overall tyrosine phosphorylation of several cellular proteins, including tau and most probably the microtubule-
were plated into 25 cm². Primary human brain neuronal cultures were established from terminal cells were cultured for 7 d before being used for the treatments described. Human cells were plated onto poly-L-lysine (10

Aβ was also observed after Aβ treatment, and immunoprecipitation of Fyn from Aβ-treated neurons showed an increase in association of Fyn with Aβ. Concomitant with these rapid changes in tyrosine phosphorylation of cellular proteins, Aβ treatment also activated ERK2. The rapid changes in FAK/Erk and tau tyrosine phosphorylation reported here may be critical early pathogenic events initiated by Aβ. Furthermore, because the tyrosine phosphorylation changes preceded neuronal death by many hours, Aβ stimulation of these signaling events is likely to be a rapid event but with long-term effects.

MATERIALS AND METHODS

All chemicals were purchased from Sigma (Gillingham, UK), unless otherwise stated. The Src family kinase inhibitor PP2, the PI3-kinase inhibitors wortmannin and LY 294002, and the MEK activation inhibitor PD 98059 were obtained from Calbiochem (Nottingham, UK). The Aβ-derived pentapeptide containing amino acids 25–35 (Aβ25-35), the reverse sequence 35–25 (Aβ35-25), and 1–42 (Aβ1-42) were obtained from Bachem (Essex, UK). Aβ25-35 and Aβ35-25 were resuspended in sterile distilled H2O at a concentration of 2 mM and incubated at 37°C for 1 hr to allow fibril formation (Terzi et al., 1994). Aβ1-42 was resuspended in 50% (v/v) PBS/stéllate distilled H2O at a concentration of 1.5 mg/ml and incubated at 37°C for 7 d to allow fibril formation (Serpell, 2000). Soluble Aβ25-35, was prepared immediately before use by resuspending Aβ25-35 in sterile distilled H2O at a concentration of 1 mg/ml. Anti-phospho-ERK monoclonal antibody (mAb) was obtained from New England Biolabs (Hitchin, UK). Anti-ERK polyclonal antibody (pAb) and anti-Fyn mAb were obtained from Transduction Laboratories (Lexington, KY). Anti-MAP2c mAb HM-2 was obtained from Sigma. Anti-phosphorysine mAb 4G10 was obtained from Upstate Biotechnology (Lake Placid, NY). Anti-FAK pAb C20 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Protein A/G Plus was obtained from Autogen Bioclear (Wiltshire, UK). mAb PHF-1 was provided by Dr. P. Davies (Department of Pathology, Albert Einstein College of Medicine, Bronx, NY). SHP-1 tyrosine phosphatase was cloned and expressed by one of our collaborating laboratories. Horseradish peroxidase (HRP)-conjugated donkey anti-rabbit and anti-mouse IgG were obtained from Amersham Pharmacia (Buckinghamshire, UK).

Primary cortical neuronal cultures. Neuronal cultures were prepared from embryonic day 18 rat embryos as described previously (Davis et al., 1995). Essentially, embryos were removed, and their fetal brain cortices were dissected and freed of meninges. The cells were dissociated by trypsinization (0.25% (v/v) for 20 min at 37°C). Trypsinization was stopped by washing three times in Neurobasal medium (Life Technologies, Paisley, UK) containing 10% (v/v) fetal calf serum (FCS) (Autogen Bioclear). Brain cortices were identified on the basis of their large size and presence of convolutions (immature gyri). Cell dissociation and culture procedures were essentially identical for rat and human tissue except that human cells were plated onto polyl-lysine (10 μg/ml)-coated glass coverslips in 12-well tissue culture plates, or 4 × 10⁶ neurons were plated into 25 cm² flasks (Marathon, Harrow, UK) and maintained in Neurobasal medium containing B27 supplement (Life Technologies), 2 mM glutamine, and 20 μg/ml gentamycin solution. Rat brain primary cells were cultured for 7 d before being used for the treatments described. Primary human brain neuronal cultures were established from terminations of pregnancy at 14–20 week gestation through collaboration with King’s College Hospital, Ethical Committee approval No. 1997-0037. Brain cortices were identified on the basis of their large size and presence of convolutions (immature gyri). Cell dissociation and culture procedures were essentially identical for rat and human tissue except that human cells were plated onto polyl-lysine (10 μg/ml)-coated and laminin (5 μg/ml)-coated glass coverslips in 12-well tissue culture plates or into 25 cm² flasks. Cells were cultured for 14 d before showing them to attain a fully polarized phenotype similar to 7-d-old rat primary cells (our unpublished observations), with a change of medium every third day before they were used for the treatments described.

Cell treatments. Cells were treated with the appropriate peptide for the indicated times in culture medium. In some instances cells were pre-treated with 30 μM PP2 for 18 hr, 20 μM PD 98059 for 45 min, 100 μM LY 294002 for 15 min, 100 μM wortmannin for 15 min, 10 μM bis-indolylmaleimide for 45 min, or 25 mM LCl1 for 4 hr.

Enrichment of PHF-tau from AD brain. Gray matter from an AD brain was obtained from The London Neurodegenerative Diseases Brain Bank (Department of Neuropathology, Institute of Psychiatry) and hand-homogenized in a glass Dounce homogenizer in ice-cold Buffer A [100 mM 2-(morpholino)ethanesulfonic acid (MES), pH 6.5, 0.5 mM MgCl2, 1 mM EGTA, 1 mM NaF, 50 mM Na-acetate, 0.5 mM sodiumorthophosphate, 10 mM NaH2PO4 monohydrate, and 0.5 mM PMSF], using 4 ml Buffer A per gram of tissue. Insoluble material was removed from the homogenate by centrifugation at 27,000 × g (average) at 4°C for 30 min. The pellet was discarded, and the supernatant was centrifuged at 95,000 × g (average) at 4°C for 1 hr. The resultant supernatant was resuspended in Buffer B (10 mM Tris-HCl, pH 7.4, 4 mM guanidine-HCl, 10 mM DTT, 50 mM Na-acetate, 50 mM imidazole, 25 mM β-glycerophosphate, 20 mM NaF, 10 mM Na pyrophosphate, and 0.5 mM PMSF), using 0.5 ml Buffer B per gram of starting material for 2 hr at room temperature. The resulting suspension was centrifuged at 95,000 × g (average) at 4°C for 1 hr. The supernatant was retained and dialyzed overnight at 4°C against 8 l of Buffer C (20 mM bis-Tris-propane, pH 7.0, and 1 mM DTT) before centrifugation at 95,000 × g (average) at 4°C for 1 hr. The resultant supernatant was boiled for 10 min, then cooled on ice and centrifuged at 95,000 × g (average) at 4°C for 1 hr. The supernatant was retained.

Western blotting, tyrosine phosphatase treatment, and immunoprecipitations. Cells were washed three times in ice-cold TBS (25 mM Tris, pH 8.0, 140 mM NaCl, and 5 mM KCl) and lysed by scraping into ice-cold radioimmunoprecipitation assay (RIPA) buffer [1% (v/v) Triton, 0.1% (v/v) SDS, 0.5% (v/v) deoxycholate, 20 mM Tris, pH 7.4, 150 mM NaCl, 10 mM NaF, 1 mM NaVO4, 1 mM EDTA, 1 mM EGTA, and 0.2 mM PMSF] and left to stand for 20 min on ice. Insoluble material was removed by centrifugation at 15,800 × g (average) at 4°C for 10 min. Heat-stable fractions were prepared by scraping cells into ice-cold TBS and centrifuging at 15,800 × g (average) at 4°C for 10 min. The supernatant was discarded, and the pellet was resuspended in 100 μl MES/NaCl buffer (100 mM MES, 1 mM NaCl, 0.5 mM MgCl2, 1 mM EGTA, 2 mM DTT, 1 mM NaVO4, 1 mM benzamidine hydrochloride, 5 μg/ml leupeptin, 2 μg/ml aprotinin, 20 μg/ml pepstatin, 0.5 μM PMSF) and immediately heated to 100°C for 10 min followed by cooling by immersing in ice and then centrifuged at 15,800 × g (average) at 4°C for 25 min. The supernatant that was enriched in tau and MAP2c was retained. Protein concentrations were quantified by the method of Bradford (1976). Before electrophoresis, samples were mixed with equal volumes of 2× SDS-PAGE sample buffer (Sigma), heated to 100°C for 5 min, and then centrifuged at 15,800 × g (average) for 5 min. Proteins were resolved by SDS-PAGE using 10% (w/v) gel and transferred by electroblotting to nitrocellulose (Schleicher & Scuell, Dassel, Germany) and submerged in blocking buffer TBS-Tween [TBS containing 0.2% (v/v) Tween 20 and 3% (w/v) nonfat dried milk] for 1 hr at room temperature. Blots were incubated with primary antibody diluted in blocking buffer overnight at 4°C. Blots were washed three times in PBS-Tween and incubated with HRP-linked secondary antibodies diluted in blocking buffer for 1 hr. After an additional three washes in TBS-Tween, antibody binding was detected by an enhanced chemiluminescence (ECL) system (Amersham Pharmacia).

Phosphorysine antibody detection, blocking buffer and primary antibody buffer contained 4% (w/v) BSA instead of 3% (w/v) nonfat dried milk. To reprobe blots, nitrocellulose was stripped by washing in 100 mM 2-mercaptoethanol, 2% (w/v) SDS, 62.5 mM Tris-HCl, pH 6.7, followed by incubation in Buffer C (20 mM bis-Tris-propane, pH 7.0, 100 mM 2-mercaptoethanol, 2% (w/v) SDS, 62.5 mM Tris-HCl, pH 6.7, containing 8.6 μg/ml His-tagged full-length SHP-1 for 2 hr at room temperature with occasional agitation.

Immunoprecipitations were performed by incubation of cell lysates (400 μg total protein) with 1 μg primary antibody for 2 hr at 4°C followed by addition of 20 μl protein A/G PLUS-Agarose and a further incubation of 1.5 hr at 4°C. The mixture was then centrifuged at 15,800 × g (average) at 4°C for 5 min, and the supernatant was removed at 4°C until analysis. The beads were washed four times in ice-cold RIPA buffer. After the final wash, the beads were resuspended in 40 μl SDS-PAGE.
sample buffer, heated to 100°C for 10 min, resolved by 7.5% (w/v) polyacrylamide SDS-PAGE, and Western blotted as described above.

Characterization of tyrosine phosphorylated tau antibody. The pAb 121–3 was raised in rabbit to a synthetic tyrosine phosphorylated peptide of tau corresponding to residues 21–36 of human tau [largest isof orm with two N-terminal inserts and four C-terminal repeats (2N4R)] and so recognizes tau when it is phosphorylated at Tyr29. The specificity of the 121–3 antibody was tested on 2N4R recombinant tau that was either unphosphorylated or phosphorylated on tyrosine residues as follows: 5 μl (24 μg) of 2N4R recombinant tau was added to 51 μl reaction mixture (50 mm Tris-HCl, pH 7.5, 1 mM ATP, 10 mM MgCl2, 5 mM MnCl2, 0.1 mM EDTA, 10 μM Na3VO4, and 1 mM DTT) and incubated in the presence (for phosphorylation) or absence (control, unphosphorylated) of 4 μl lck at 30°C for 2 hr. The reaction was stopped by addition of 2X SDS-PAGE sample buffer and heating to 100°C for 5 min. Unphosphorylated or phosphorylated tau (0.4 μg) was resolved by SDS-PAGE using 10% (w/v) polyacrylamide, transferred to nitrocellulose, and probed with antibodies TP70, 121–3, and 4G10 as indicated. Arrowhead indicates the tau band; arrow indicates the lck band.

Immunofluorescence microscopy. Cultures were fixed in 4% (w/v) paraformaldehyde (PFA) for 30 min at room temperature, permeabilized with 0.2% (v/v) Triton X-100 in TBS for 10 min, and blocked in 5% (v/v) FCS/0.2% (w/v) Tween 20 in TBS for 30 min. Primary antibody was diluted in blocking solution and incubated for 1 hr. FAK and Fyn were detected by TP70 because of its increased phosphorylation. The phosphorylated tau displays a slightly reduced electrophoretic mobility compared with the unphosphorylated tau as detected by TP70 because of its increased phosphorylation. The lck band is labeled by the 4G10 antibody because of autophosphorylation.

RESULTS

Aβ activates caspases during the neurotoxic response of rat and human fetal brain neurons.

To establish conditions of Aβ neurotoxicity, Aβ25–35 was aged to produce aggregated Aβ25–35 and applied to rat or human primary neuronal cultures in Neurobasal medium either with or without supplements. Cells were stained for activated caspases after exposure to Aβ25–35 for different times, and cell lysis was monitored by release of LDH. Typical results after different exposure times to Aβ are illustrated in Figure 2. The earliest time at which caspase activation and LDH release could be observed was ~24 hr and was maximal at 96 hr. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo phenyl)-2H-tetrazolium, inner salt (MTS) assay was also used to monitor neurotoxicity and showed a reduction of 30% of the ability of the cells to reduce MTS after 24 hr of Aβ25–35 treatment and was complete at 72 hr (data not shown). The reverse sequence Aβ35–25 induced no detectable cell death by the LDH or MTS assays, and the presence or absence of B27 supplement did not affect the neurotoxic response. All subsequent experiments were thereafter performed in Neurobasal medium supplemented with B27.
Aβ treatment induces a rapid elevation of tyrosine phosphorylation of neuronal proteins

To identify possible early cellular responses to Aβ treatment that precede measurable cell death, changes in phosphotyrosine content of neuronal proteins were investigated because tyrosine phosphorylation is often an early signaling event. Total cell lysates analyzed by Western blotting with the phosphotyrosine-specific monoclonal antibody 4G10 showed that exposure of rat neuronal cultures to Aβ25-35 resulted in a rapid increase in the phosphotyrosine content of numerous proteins (Fig. 3A). There was an increase in the tyrosine phosphorylation content of at least eight bands ranging between relative molecular masses of 38 and 120 kDa. The increase in phosphotyrosine content of all of these proteins was already very marked after 1 min exposure to Aβ25-35 but was partially transient, peaking at 2 min after exposure and declining thereafter.

Similar patterns of changes were obtained for total cell lysates of Aβ-treated primary human brain cortical cultures (Fig. 3B). There was an increase in tyrosine phosphorylation of approximately seven or eight bands. Again, the increase in the phosphotyrosine content of most of these proteins was marked after 1 min Aβ treatment and peaked at 2 min after exposure. However, unlike the primary rat cortical cultures, the phosphotyrosine content of these proteins had declined to control untreated levels by 10 min after exposure. Treatment of primary rat neuronal cultures with soluble Aβ25-35 did not result in an increase in the phosphotyrosine content of any proteins (data not shown).

Exposure of rat neuronal cultures to the full-length fibrillar Aβ peptide, Aβ1-42, also resulted in an increase in the phosphotyrosine content of neuronal proteins, although in this experiment the peak was somewhat delayed to ~5 min, and the increase in phosphotyrosine content was less marked than in Aβ25-35-treated cultures (Fig. 4A). Tyrosine phosphatase treatment of the blot with SHP-1 completely abolished the 4G10 signals for both control and Aβ1-42-treated samples (Fig. 4B). Subsequent stripping and reprobing of the blot with the mAb PHF-1, which detects tau phosphorylated at its serine 396 and serine 404 residues, revealed a band at ~56 kDa (Fig. 4C). This confirmed that the 4G10 immunoreactivity reflected neuronal protein tyrosine phosphorylation and was not caused by protein phosphorylation on other residues or nonspecific reactivity. Figure 4D shows an identically loaded Coomassie-stained gel, demonstrating equal protein loading.

To identify some of the proteins that exhibited increased tyrosine phosphorylation, heat-stable fractions from the cultures were analyzed because selected proteins are easily enriched by heat treatment, including tau, which is important in Alzheimer’s disease and has previously been shown to be tyrosine phosphorylated under certain experimental conditions (Lee et al., 1998). Western blots with 4G10 of heat-stable fractions from control and Aβ25-35-treated rat and human primary neuronal cultures resulted in very similar patterns of labeled proteins (Fig. 5A). Control cultures had essentially a single strong band of apparent molecular mass 77 kDa, with weakly labeled material of slightly lower mobility (lanes 1 and 4). Aβ25-35 treatment of both rat and
Western blots of the heat-stable fractions were probed with monoclonal antibody to MAP2, HM-2, and the polyclonal antibody to tau, TP70. The 77 kDa species was labeled by HM-2 (Fig. 5A, lane 6), suggesting that this material is most likely MAP2c, and the 58 kDa species was labeled by TP70, again suggesting that it is tau (Fig. 5A, lane 7). TP70 was raised against a synthetic C-terminal peptide of tau that shares sequence homology with the C terminus of MAP2c and has previously been shown to recognize both tau and MAP2c (Brion et al., 1993a), hence the labeling of both bands by TP70 in Figure 5A (lane 7). Thus, the fact that this 77 kDa species is heat stable and labeled by two antibodies that recognize MAP2c strongly suggests that it is identical with MAP2c, although we cannot formally rule out another phosphotyrosine-containing protein comigrating at this point. Densitometric analysis of the Western blots showed that Aβ treatment gave maximum increases in the phosphotyrosine content of approximately fivefold for the putative MAP2c and fourfold for tau.

To confirm that the increase in phosphotyrosine content of the 58 kDa species is indeed caused by an increase in phosphotyrosine content of tau, Western blots of total cell lysates from control untreated and Aβ-treated primary human brain cortical cultures were probed with the phosphotyrosine tau-specific pAb 121–3, which revealed that the increase in the phosphotyrosine labeling of the 58 kDa species was caused by an increased phosphotyrosine content of tau (Fig. 5B). The response in this experiment was both rapid and transient, peaking at 1 min after exposure. The increase in tyrosine phosphorylation of tau was specific to Aβ treatment and was not caused by an increase in the overall levels of tau as demonstrated by TP70 labeling (Fig. 5C). Thus, the increase in labeling by 4G10 of the band migrating in the position of tau is clearly attributable to a genuine increase in the phosphotyrosine content of tau and not to some other protein comigrating with tau, because the polyclonal antibody 121–3 is specific to phosphorylated tyrosine 29 within the human tau sequence.

**Src family PTKs are involved in Aβ-induced increases in protein phosphotyrosine content**

The compound PP2 inhibits members of the Src family of PTKs such as Src and Fyn. Cultures of primary rat neurons were pretreated with 10 μM PP2 for 18 hr before exposure to Aβ25–35 and heat-stable proteins were probed with 4G10. Figure 5D shows that PP2 pretreatment completely prevented the rapid increase in phosphotyrosine content of tau and putative MAP2c in response to exposure to Aβ25–35 (lanes 1 and 3). It is also apparent that pretreatment of cultures with PP2 reduces the basal levels of tyrosine phosphorylation of both cytoskeletal proteins (compare lane 3 with lane 1). Pretreatment of these rat cortical cultures with the protein kinase C (PKC) inhibitor bis-indoylmaleimide (lane 4), and Aβ25–35 for 5 min in culture pretreated with the PI3-kinase inhibitor wortmannin for 15 min (lane 5). Apparent molecular mass (kDa) markers are indicated to the left. Bands labeled MAP2c and tau in A had an interpolated molecular mass of 77 and 58 kDa, respectively.

Human cultures resulted in a marked increase in intensity of labeling of this 77 kDa band and the appearance of a second band at ~58 kDa (lanes 2 and 5). Aβ25–35 treatment of human but not rat neurons also resulted in the appearance of a band at ~29 kDa (lane 5). These were the only 4G10-immunoreactive species reproducibly observed in the heat-stable fractions from the cultures. 4G10 Western blots of the reverse sequence Aβ25–35-treated cultures were indistinguishable from control cultures, demonstrating that the response was specific for the neurotoxic peptide (rat cultures treated with Aβ25–35, lane 3; treatment of human cells with Aβ25–35 not shown). Similar results were obtained using the polyclonal antibody PY20, which also detects phosphotyrosine residues (data not shown).

**PHF-tau is tyrosine phosphorylated**

Because Aβ treatment of neurons in culture clearly resulted in an increase in tyrosine phosphorylation of tau, we reexamined PHF-
tau isolated from AD brain for evidence of tyrosine phosphorylation. Partially purified PHF-tau from selected cases was labeled on Western blots by 4G10 in a pattern that was identical to labeling with the polyclonal tau antibody PHF-1 (Fig. 6A). The labeling by 4G10 was weaker than PHF-1, and it was found to be necessary to enrich for PHF-tau to observe clear labeling by 4G10, suggesting that the phosphotyrosine content is lower than the level of phosphorylation at the PHF-1 epitope (serines 396 and 404) (Otvos et al., 1994). Figure 6B confirms that the labeling of PHF-tau by 4G10 is the result of a portion of PHF-tau containing tyrosine in a phosphorylated state because at least two of the PHF-tau bands were labeled by pAb 121–3. The difference in pattern between 4G10 and pAb 121–3 may be because not all species of PHF-tau contain the same levels of Tyr29 in a phosphorylated state and the tyrosine residues probably also exist in a dephosphorylated state.

Furthermore, tau extracted from neurologically unimpaired individuals is not labeled by the pAb 121–3. We have not observed labeling of tau from control postmortem human brain by 4G10, and we were unable to label adult rat brain tau with 4G10, even after the brain was immediately immersed in liquid nitrogen and the tau extracted in buffers containing phosphatase inhibitors. However, tau from neuronal cultures, which is equivalent to fetal brain tau, is weakly labeled by 4G10 (Fig. 5D, lane 1).

Aβ induces association of FAK with Fyn and increased tyrosine phosphorylation of FAK

Because Aβ is applied externally to neurons in paradigms of Aβ neurotoxicity, it is reasonable to assume that it stimulates intracellular PTKs via a plasma membrane receptor and signaling complex. It has previously been reported that Aβ treatment of a neuroblastoma cell line (rat CNS B103 neuroblastoma cells) resulted in an increased level of FAK tyrosine phosphorylation, but only after 48 hr of Aβ treatment (Zhang et al., 1994). A related non-receptor tyrosine kinase PYK2 has also been reported to phosphorylate tyrosine on proteins in response to Aβ in microglial cells (Combs et al., 1999). Because PP2, an inhibitor of the Src family of non-receptor tyrosine kinase PYK2 has also been reported to phosphorylate tyrosine on proteins in response to Aβ in microglial cells (Combs et al., 1999). Because PP2, an inhibitor of the Src family of non-receptor tyrosine kinases, blocked Aβ-induced tyrosine phosphorylation of tau and the putative MAP2c and Fyn can be found in the same neuronal compartments, i.e., perikarya and the neuritic network (Fig. 7A, B). Total cell lysates of primary rat cortical cultures contained both Src and Fyn, and the levels of these proteins as assessed by Western blot of total cell lysates did not change after exposure to Aβ (data not shown). Neurons were left untreated or were exposed to Aβ25-35 or the reverse sequence Aβ35-25 and harvested at different times after exposure in RIPA buffer. Proteins were immunoprecipitated with polyclonal antibodies to either Fyn or Src. The immunoprecipi-
tates were probed on Western blots using 4G10 or antibodies to FAK, Fyn, or Src. There was no difference in the amount of Fyn immunoprecipitated after the different treatments (Fig. 7C), and it was found that FAK in control neurons (untreated) coprecipitated with Fyn, and exposure to Aβ25-35 resulted in an increase in the amount of FAK associated with Fyn (Fig. 7D). The FAK that was complexed with Fyn from untreated neurons was very weakly tyrosine phosphorylated, but exposure of neurons to Aβ25-35 resulted in a marked increase in phosphotyrosine content of FAK, indicative of an activation of FAK (Fig. 7E). The reverse sequence Aβ25–35 did not result in a similar activation of FAK (Fig. 7E, lane 6). No association between Src and FAK was observed in either untreated or treated cells (data not shown), and no evidence for the expression of PYK2 was found in our neuronal cultures (data not shown). Kinase assays of Fyn immunoprecipitated from Aβ25–35-treated primary neuronal cultures revealed a high level of kinase activity in both Aβ25–35-treated and control untreated cultures, suggesting that Aβ treatment does not result in an increase in activation of total Fyn kinase; rather it results in a relocalization of active Fyn to FAK.

The above experiments showed that the FAK that is associated with Fyn is also tyrosine phosphorylated specifically in response to Aβ25–35 treatment. To determine whether the increased tyrosine phosphorylation of FAK represented a significant fraction of the total cellular FAK, immunoprecipitation of FAK from both rat and human neuronal cultures was performed. Figure 8 A and B, show that indeed there was a marked increase in tyrosine phosphorylation of total cellular FAK in response to Aβ25–35 treatment of rat and human neurons, respectively. The kinetics of FAK activation appeared to be similar in rat and human neurons, although there was apparently a slightly longer delay to peak activation in human neurons (Fig. 8B) compared with rat (Fig. 8A). The peak level of 4G10 labeling indicated a four- to fivefold increase in FAK tyrosine phosphorylation in both rat and human neurons. The levels of immunoprecipitated FAK protein remained constant during the course of Aβ25–35 exposure (data not shown). The increased tyrosine phosphorylation of FAK was also observed after treatment of rat neurons with full-length Aβ1–42 (Fig. 8C), and thus, like the increase in content of phosphotyrosine of numerous neuronal proteins (Fig. 3), the signaling responses are also not restricted to the shorter neurotoxic peptide.

**Aβ-induced FAK activation involves PI3-kinase and Fyn but not PKC**

Cellular responses of neurons to Aβ treatment have implicated activation of a number of protein kinases. Physiological levels of Aβ (1 nM) have been reported to activate PI3-kinase through a tyrosine signaling cascade (Luo et al., 1996). Aβ has also been found to activate the MAP kinase pathway, and lithium has been shown to protect against the toxic effect of Aβ, which indicates the involvement of GSK-3β in cell death (Luo et al., 1997; G. Alvarez et al., 1999; Wei et al., 2000). To determine which, if any, of these pathways acts on FAK tyrosine phosphorylation, the cultures were either left untreated or pretreated with LY 294002 (LY), PD 98059 (PD), bis-indolylmaleimide (Bis), lithium (Li), or PP2 or left untreated as outlined in Materials and Methods were either harvested without further treatment (C) or treated with Aβ25–35 (10 μM) for 5 min (Aβ); a further culture was treated with glutamate (1 mM) alone for 1 hr (G). Apparent molecular mass (kDa) is indicated on the left.

**Figure 8.** The rate of Aβ-induced FAK activation is similar in primary rat brain cortical cultures and primary human brain cortical cultures. A, B, Western blots with 4G10 of protein immunoprecipitated with anti-FAK polyclonal antibody from cell lysates of 7-d-old primary rat cortical cultures (A) and of 14-d-old human cortical cultures (B). Shown are untreated cultures (lane 1) and cultures treated with Aβ25–35 (10 μM) for 1 min (lane 2), 2 min (lane 3), 5 min (lane 4), and 10 min (lane 5). C, Western blot with 4G10 of protein immunoprecipitated with anti-FAK polyclonal antibody from cell lysates of control 7-d-old primary rat cortical cultures left untreated or treated for 5 min with 10 μM Aβ25–35 or 10 μM Aβ1–42 as indicated. Apparent molecular mass (kDa) is indicated on the left.

**Figure 9.** PI3-kinase and Fyn are involved in Aβ-induced FAK activation. Shown are Western blots with 4G10 (bottom panel) and polyclonal antibody to FAK (top panel) of protein immunoprecipitated with anti-FAK polyclonal antibody from cell lysates of 7-d-old primary rat brain cortical cultures. Cultures that had been pretreated with LY 294002 (LY), PD 98059 (PD), bis-indolylmaleimide (Bis), lithium (Li), or PP2 or left untreated as outlined in Materials and Methods were either harvested without further treatment (C) or treated with Aβ25–35 (10 μM) for 5 min (Aβ); a further culture was treated with glutamate (1 mM) alone for 1 hr (G). Apparent molecular mass (kDa) is indicated on the left.
untreated levels, suggesting that any activation of MAP kinase or GSK-3 by Aβ occurs downstream of FAK signaling or through an independent pathway. The inability of bis-indolylmaleimide to inhibit Aβ-stimulated FAK phosphorylation suggests that FAK activation under these conditions is not a PKC-dependent mechanism, in contrast to FAK activation in response to glutamate or acetylcholine (Slack, 1998; Tang et al., 1999). Figure 9 (top panel) shows that the increases in tyrosine phosphorylation observed under the different conditions was not caused by an increase in the levels of FAK that were immunoprecipitated. The ability of both LY 294002 and PP2 to prevent the Aβ-induced FAK phosphorylation suggests that both Fyn and PI3-kinase may be involved in FAK activation. Both Fyn and PI3-kinase can associate with FAK through their SH2 domains when FAK is phosphorylated at its autophosphorylation site, Tyr^397 (Cobb et al., 1994; Chen et al., 1996). The ability of LY 294002 to prevent the Aβ-stimulated increase in FAK tyrosine phosphorylation suggests that both PI3-kinase and Fyn may be involved in FAK activation, either through direct binding of their SH2 domains to FAK or through SH3 domain interactions between PI3-kinase and Fyn (Renzoni et al., 1996; Wellbrock and Schartl, 2000). In addition, pretreatment of cultures with the calcium chelator EGTA failed to prevent the Aβ-induced FAK tyrosine phosphorylation (data not shown).

Inhibitors of FAK tyrosine phosphorylation prevent Aβ-induced ERK2 activation in primary neuronal cultures

It has previously been reported that Aβ can stimulate the MAP kinase signaling pathway involving activation of ERK1 and ERK2. Because FAK in certain cellular systems has been reported to be upstream of MAP kinase, we investigated the possibility that ERK1 and ERK2 activation in response to Aβ_{25-35} treatment is also induced by FAK in neurons. Western blots of rat neuronal cultures with a non-phosphorylation-dependent monoclonal antibody to ERK1 and ERK2 showed that the majority of MAP kinase was represented by ERK2 (Fig. 10A, top panel). Treatment of rat neuronal cultures with Aβ_{25-35} for 5–60 min caused a sustained increase in the activation of ERK2 as detected by monoclonal antibodies to the dually phosphorylated threonine-202 and tyrosine-204 epitope (Fig. 10A, lane 2–5). No activation of ERK1 was detected, albeit the level of ERK1 was much lower than ERK2. Pretreatment of cultures with the compounds PD 98059 (Fig. 10A, lanes 8 and 9) or LY 294002 (lanes 10 and 11) and harvesting without further treatment or with subsequent exposure to Aβ_{25-35} for 5 min prevented any Aβ-induced increase in ERK2 activity without affecting the total ERK protein levels. Pretreatment with PP2 for 18 hr apparently reduced the total levels of ERK protein (Fig. 10A, lanes 6 and 7) and also inhibited Aβ-induced ERK2 activation by 50% (lane 7). Figure 10B shows the relative amounts of active ERK found in each sample. Taken together, the results suggest that Aβ activates ERK2 in a MEK-dependent manner and that ERK activation is downstream of FAK tyrosine phosphorylation and PI3-kinase and Fyn.

DISCUSSION

The importance of Aβ deposition in the brain in AD is strongly implicated from genetic studies. All three genes, β-amyloid precursor protein, presenilin 1, and presenilin 2, now known to cause AD have been shown to cause an increase in Aβ production or an increase in the ratio of Aβ_{25}/Aβ_{42}, both of which drive aggregation (Scheuner et al., 1996; Citron et al., 1997). Possession of one or two E4 alleles of apolipoprotein E also results in increased Aβ deposition in the brain before clinical symptoms arise (Polvikoski et al., 1995). It is now generally accepted that deposition of diffuse deposits of Aβ in the brain is an early event in the development of AD, and neurotoxicity of Aβ is well established in in vitro models. There is still a lack of agreement on the physical nature of the neurotoxic form of Aβ, but fibrils reproducibly damage cultured neurons, although the mechanisms leading to cell death are not established and reports are often contradictory (Abe and Saito, 2000; Marin et al., 2000; Troy et al., 2000). The early deposition of Aβ in the pathogenic sequence emphasizes the importance of elucidating the initial response of neurons to Aβ fibrils.

Here we confirm that Aβ-derived neurotoxicity in culture is slow, in agreement with earlier observations (Behl et al., 1994; Estus et al., 1997; Abe and Saito, 2000; Grieve et al., 2000). Cell death could not be detected before 24 hr, with a rise in caspase activity concomitant with LDH release and with complete cell death in cultures occurring slowly over 96 hr. This is similar to reported glutamate-induced excitotoxic mechanisms, in which a marked increase in LDH release in response to glutamate was measured only after 18–24 hr (Gray and Patel, 1995). However, glutamate does induce early and irreversible changes before cell death, in particular Ca^{2+} influx (Randall and Thayer, 1992), membrane depolarization, and activation of postsynaptic cell membrane receptors with subsequent opening of ion channels, resulting in a disturbed intracellular ionic environment, which then inevitably results in cell death (Rothstein, 1996). We therefore looked for early responses to Aβ because they too may be the critical events in neurotoxicity.

Here we report a rapid and somewhat transient rise in tyrosine phosphorylation of cellular and cytoskeletal proteins in response to Aβ fibrils.

Figure 10. Aβ-induced ERK phosphorylation is downstream of FAK activation. A. Western blots of RIPA buffer lysates from control 7-d-old primary rat cortical cultures (lane 1) and cultures treated with Aβ (10 μM) and harvested after 5 min (lane 2), 10 min (lane 3), 30 min (lane 4), 60 min (lane 5), with PP2 alone (30 μM) for 18 hr (lane 6), Aβ_{25-35} for 5 min in culture pretreated with PP2 (lane 7), PD 98059 alone (lane 8), Aβ_{25-35} for 5 min in culture pretreated with PD 98059 (lane 9), LY 294002 alone (lane 10), and Aβ_{25-35} for 5 min in culture pretreated with LY 294002 (lane 11). Top panel blot was probed with monoclonal antibody MK12 to ERK; bottom panel blot was probed with a monoclonal antibody E10 to phosphorylated ERK1 (p44) and ERK2 (p42). B, Quantification of ERK kinase phosphorylation of the experiments shown in A. The activity, as indicated numerically beneath the abscissa, is expressed relative to the control (0 min) that was normalized to 1.
to both $\alpha_\beta_{25-35}$ and $\alpha_\beta_{1-42}$. The shorter $\alpha_\beta_{25-35}$ was shown to be more potent than the full-length $\alpha_\beta_{1-42}$ at eliciting an increase in tyrosine phosphorylation, consistent with previously reported findings (Varadarajan et al., 2001). The peak increase in tyrosine phosphorylation was variable, usually being slower in human neuronal cultures, but precise measurement over short times in this type of cellular response is problematic. Calcium ions were not required for the phosphorylation of FAK in response to $\alpha_\beta_{25-35}$. Previous reports of $Ca^{2+}$ influx in $\alpha_\beta$-induced cell death suggest that parallel pathways may be activated in response to $\alpha_\beta$ (Luo et al., 1995; Ekinci et al., 1999; MacManus et al., 2000). Tyrosine phosphorylation changes often serve to activate downstream serine/threonine kinases. The response involved Fyn but not Src and an activation of FAK and increased association of FAK with Fyn. These changes are similar to activation of FAK and Fyn in other cell signaling systems such as integrin signaling. Other workers have reported tyrosine kinase activation in microglial cultures using higher concentrations of $\alpha_\beta$ (50 $\mu$M), but we now show that this occurs in neurons in response to 10 $\mu$M $\alpha_\beta_{25-35}$ (McDonald et al., 1998). Fyn activation is likely to be important in $\alpha_\beta$ neurotoxicity because Fyn knock-out mice are reported to be resistant to ADDL toxicity (Lambert et al., 1998).

MAP kinase has previously been reported to be activated in microglial and THP1 monocyte cultures after administration of high concentrations of $\alpha_\beta$ (Combs et al., 1999); however, the activation was transient. Now we show that ERK activation is rapid and sustained and that this is consistent with it being downstream of FAK association with Fyn. Furthermore, in our neuronal cultures, PI3-kinase appears to be required for ERK activation in response to $\alpha_\beta$ treatment. This is consistent with previous reports in which inhibition of PI3-kinase blocked the activation of ERK2 by integrin in fibroblast cell lines (King et al., 1997; Finkelstein and Shimizu, 2000).

Tau has been shown to be tyrosine phosphorylated in COS7 cells doubly transfected with Fyn and tau (Lee et al., 1998). We therefore investigated whether tau is tyrosine phosphorylated in response to $\alpha_\beta$ treatment and found that both tau and most likely MAP2c are tyrosine phosphorylated in neurons and that the kinetics of tyrosine phosphorylation mimic the kinetics of FAK activation and FAK/Fyn complex formation. Furthermore, the ability of PP2 to prevent the $\alpha_\beta$-induced tyrosine phosphorylation of tau and MAP2c strongly suggests that tau and MAP2c are indeed substrates of Fyn in the response to $\alpha_\beta$. It was therefore important to search for evidence of tyrosine phosphorylation of cytoskeletal proteins in AD brain, and we discovered that PHF-tau is indeed tyrosine phosphorylated. On the other hand, we could not demonstrate tyrosine phosphorylation of normal adult brain tau, although fetal brain tau has a low level of tyrosine phosphorylation. Thus, it might be that the tyrosine phosphorylation of PHF-tau is another example of the phosphorylation state mimicking the fetal phosphorylation of tau (Kanemaru et al., 1992; Bramblett et al., 1993; Brion et al., 1993b; Goedert et al., 1993; Watanabe et al., 1993). Further work needs to be done to establish whether this tyrosine phosphorylation may trigger aggregation of tau to produce PHF-tau and whether it influences the phosphorylation of tau by serine/threonine protein kinases. It is also of interest to determine whether all or only some of the tyrosine residues in tau are phosphorylated, and so far using a specific antibody we have shown that tyrosine 29 is phosphorylated in human tau in response to $\alpha_\beta$ exposure and in PHF-tau. However, the difference in the labeling pattern of PHF-tau with this antibody and 4G10 suggests that there may be heterogeneity of tyrosine phosphorylation in PHF-tau. We also had to enrich the PHF-tau fraction to obtain labeling with phosphotyrosine-specific antibodies, and not all cases of AD brain showed evidence of tyrosine phosphorylation of PHF-tau. This may well be attributable to the more labile nature of tyrosine phosphorylation compared with serine and threonine phosphorylation.

FAK levels in the adult brain are found to be at their highest in the cerebral cortex and hippocampus (Burgaya et al., 1995). FAK serves as a regulated adaptor protein, recruiting other proteins by autophosphorylation of its tyrosine997 residue, a high-affinity binding site for SH2 domains of Fyn, Src, and PI3-kinase (Chen and Guan, 1994; Cobb et al., 1994; Schaller et al., 1994). Binding of these kinases can in turn enable them to phosphorylate tyrosine residues in the C-terminal region of FAK and also other cytoskeletal proteins associated with FAK. This is followed by recruitment of other proteins, resulting in the formation of large multimolecular structures capable of triggering a number of different signaling pathways.

The rapid changes reported here of FAK and Fyn association with increased tyrosine phosphorylation of FAK, with ERK activation, and elevated tyrosine phosphorylation of cytoskeletal proteins, all preceded measurable neuronal death. The activation of Fyn/FAK/PI3-kinase/MAP kinase is associated with protective (anti-apoptotic) signaling systems under normal physiological conditions, and all have been reported to be activated by $\alpha_\beta$ in different cell systems (Klinghoffer et al., 1999; Schaeffer and Weber, 1999; Sonoda et al., 1999; Lee and States, 2000). We suggest that there may be an incomplete mimicking of positive trophic signaling and that the full set of downstream changes are not activated, and hence $\alpha_\beta$ induces an abortive response that then leads to cell death.

The dual role of FAK in normal physiological and pathological processes highlights its importance as a convergence point in divergent signaling pathways. Ultimately the nature and composition of the multimolecular complexes that are formed under the physiological effects of FAK activation. Increased tyrosine phosphorylation of FAK provides a mechanism by which $\alpha_\beta$ can be coupled to signal transduction pathways exerting a major influence on cell fate decisions. Elucidation of the components of the multimolecular complexes and signaling pathways is an important step in understanding $\alpha_\beta$-induced neuronal toxicity.

REFERENCES


Slack BE (1998) Tyrosine phosphorylation of paxillin and focal adhesion kinase by activation of muscarinic m3 receptors is dependent on integrin engagement by the extracellular matrix. Proc Natl Acad Sci USA 95:7281–7286.


